Vigil Neuroscience’s (VIGL) Buy Rating Reaffirmed at Guggenheim

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “buy” rating reissued by equities researchers at Guggenheim in a research note issued to investors on Friday,Benzinga reports.

Several other research firms also recently weighed in on VIGL. William Blair initiated coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a report on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, Wedbush lifted their price objective on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Vigil Neuroscience currently has a consensus rating of “Buy” and an average target price of $19.75.

Vigil Neuroscience Stock Up 6.1 %

NASDAQ:VIGL traded up $0.14 on Friday, hitting $2.49. The stock had a trading volume of 1,836,336 shares, compared to its average volume of 3,136,496. The business’s 50-day simple moving average is $2.12 and its two-hundred day simple moving average is $3.12. The stock has a market cap of $101.91 million, a price-to-earnings ratio of -1.20 and a beta of 1.76. Vigil Neuroscience has a 52-week low of $1.49 and a 52-week high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.08. As a group, equities research analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vigil Neuroscience during the 2nd quarter valued at approximately $87,000. Renaissance Technologies LLC grew its position in Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares during the period. Walleye Capital LLC lifted its holdings in shares of Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after buying an additional 92,217 shares during the period. Verition Fund Management LLC acquired a new stake in Vigil Neuroscience during the third quarter worth about $442,000. Finally, Geode Capital Management LLC lifted its holdings in Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after acquiring an additional 66,712 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.